Primary Catalyst Driving Oral Biologics & Biosimilar Drugs Market Evolution in 2025: Rising Prevalence Of Chronic Diseases Driving Growth In The Oral Biologics And Biosimilar Drugs Market Driver

What Is the Future Outlook for the Oral Biologics & Biosimilar Drugs Market's Size and Growth Rate?
The market for oral biologics and biosimilar drugs has witnessed swift expansion in the last few years. The market size is projected to escalate from $7.19 billion in 2024 to $8.6 billion in 2025, indicating a compound annual growth rate (CAGR) of 19.6%. The spurt of growth during the historical period is influenced by an increase in chronic diseases, rising consciousness about oral biologics, an upsurge in patent expirations, and growing demand for biosimilars.

The market size of oral biologics and biosimilar drugs is projected to experience swift expansion in the upcoming years, reaching a value of $15.11 billion by 2029 with a compound annual growth rate (CAGR) of 15.1%. Various factors contributing to the growth over the forecast period include targeted therapy, heightened emphasis on preventive medicine, increment in healthcare expenditure, and an aging population. The forecast period will also see key trends such as advancement in oral delivery technology, biologics administered orally, the innovation of biosimilars, and a focus on patient-centric care.

What Is Stimulating Growth in the Oral Biologics & Biosimilar Drugs Market?
The escalating incidence of chronic illnesses such as arthritis, asthma, and cancer is anticipated to be a key driving factor for the oral biologics and biosimilar market. Extended work hours, restricted physical movement, and poor eating and drinking habits contribute to the incidence of chronic diseases. Subsequently, biologics are being increasingly deployed for the treatment of these chronic ailments. Biologics assist in activating an immune response against cancer cells, facilitating the immune system in eradicating cancer cells from the body. In May 2023, a United Nations article projected that by 2030, chronic diseases would account for 70% of global deaths, with the global burden of chronic diseases expected to reach approximately 60%. Hence, the growing incidence of chronic diseases is likely to boost the demand for biologics and biosimilars, inevitably propelling the growth of the oral biologics & biosimilar drugs market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp

Which Key Market Leaders Are Driving Oral Biologics & Biosimilar Drugs Industry Growth?
Major companies operating in the oral biologics & biosimilar drugs market include Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., Changchun High & New Technology Industries (Group) Inc., Dong Bao Pharmaceutical Co. Ltd., CP Guojian Pharmaceutical Co. Ltd., GlaxoSmithKline PLC, Concord Biotech Limited, Aurobindo Pharma Limited, H. Lundbeck A/S, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.

What Are the Emerging Trends in the Oral Biologics & Biosimilar Drugs Industry?
The creation of new insulin biosimilars is currently the most prevalent trend in the oral biologics and biosimilar market. Significant players in this sector are focusing on developing biosimilar versions of insulin, which is also encouraging rivalry among different manufacturers of biosimilars. To illustrate, Eli Lilly and Company, a US-based firm that produces oral biologics and biosimilar medications, introduced an insulin glargine biosimilar, Rezvoglar (insulin glargine-aglr) in April 2023. Insulin glargine products are utilized to enhance blood sugar control in adults, kids, and infants with type 1 diabetes and adults with type 2 diabetes.

What Are the Main Segments in the Oral Biologics & Biosimilar Drugs Market?
The oral biologics & biosimilar drugs market covered in this report is segmented -

1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others
3) By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Lymphocyte Modulators: Fingolimod, Ocrelizumab, Natalizumab
2) By Interleukin Inhibitors: Ustekinumab, Secukinumab, Guselkumab
3) By Tumor Necrosis Factor-Alpha Inhibitors: Adalimumab, Certolizumab Pegol, Golimumab

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Which Geographic Area Leads the Oral Biologics & Biosimilar Drugs Market?
The countries covered in the oral biologics & biosimilar drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

What Is Covered In The Oral Biologics & Biosimilar Drugs Global Market Report?

- Market Size Analysis: Analyze the Oral Biologics & Biosimilar Drugs Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Oral Biologics & Biosimilar Drugs Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Oral Biologics & Biosimilar Drugs Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Oral Biologics & Biosimilar Drugs Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3792

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.